Navigation Links
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
Date:9/13/2011

EXTON, Pa., Sept. 13, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today  that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze™ technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE).  Initiation of the clinical trial has triggered a milestone payment of $3 million to Halozyme.

"Routine prophylaxis with intravenous Cinryze has transformed the management of HAE for many patients who also have the option for self administration. The initiation of this first phase 2 study with a novel, subcutaneous combination product represents an exciting new development for patients and their physicians and is an important milestone for ViroPharma," commented Jennifer Schranz, MD, ViroPharma's vice president, clinical research. "Our goal is to optimize the overall convenience of self-administration therapy with a single subcutaneous injection. This is an important part of our efforts to continually enhance the Cinryze experience for both existing and future patients by providing them an alternative administration option."

"The start of this Phase 2 subcutaneous trial in patients with HAE marks a great achievement for our partnership with ViroPharma, and I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "Cinryze is the only HAE therapy approved for both routine prophylaxis against attacks along with self administration, and we expect this subcutaneous alterna
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
2. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
3. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
4. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
5. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
6. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
9. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
10. ViroPharma to Participate In Three May Healthcare Investor Conferences
11. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today ... Logo - ... "Our new corporate identity signifies our transformation into ... first predictive analytics platform for patent claim validity." ... launch of the proprietary AIA Shield™ platform, the Company commenced ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... 2011 Cell Biosciences, Inc. today announced that it ... approximately U.S. $9 million in cash. ... (MFI), an analytical technique used to detect particles and ... protein aggregation expressed by the FDA and other regulatory ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Increase Focus on Super Generics and ... http://www.reportlinker.com/p0491876/Generic-Growth-Strategies---Manufacturers-to-Increase-Focus-on-Super-Generics-and-Biosimilars-to-Drive-Revenues.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_and_Supplement ...
Cached Medicine Technology:Cell Biosciences Acquires Brightwell Technologies 2Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 2Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 3Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 4Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 5Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 6Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 7
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... briefs due to insufficient scrotal support and protection against dribbled urine and sweat. ... inventor from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ProDrop Particles ... . Each preset contains 15 seconds of unique footage that users can shrink and ... fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, and ...
(Date:8/28/2015)... ... 2015 , ... Rio Salado College joined nine educational institutions in ... of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August ... Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco was ... to take several months, but the current process, having already gone on for over ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
Breaking Medicine News(10 mins):Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3
... lawsuit,(Case #08CV5874) against long-term skilled nursing corporation Extendicare,and its ... by city at end of,release] was just filed in ... Laura Bernstein vs. Extendicare Health Services, Inc. and Extendicare,Homes, ... residents who lived in,a Minnesota Extendicare facility from Oct. ...
... Air Methods Corporation,(Nasdaq: AIRM ) announces the following Webcast:, ... November 6, 2008 @ 4:15 p.m. ET, ... Live over the Internet -- Simply log on to the ... address above., Contact: Christine Clarke of Air Methods ...
... Eating Disorders, PHOENIX, Oct. 30 As the ... worried about treatment and not,seeking the help they desperately ... an eating disorder can be very,serious because they can ... director of psychological services at Remuda Ranch,Programs for Eating ...
... Jeffrey A. Niezgoda and Dr. Peter J. Sordi provide updates on a wide ... - John St. John, Ph.D. gives perspectives on design and features of ... ... ULU ) --,Clinical updates and new case studies on the application of Altrazeal(TM) ...
... Personal Genetics Company Singled Out for Pioneering Retail Genomics , ... ... Magazine announced today that the Personal Genome Service™ from 23andMe ... was chosen as the year,s most significant invention for its exceptional ...
... more than $6 million dollars have been awarded to ... Institute for Medical Research (WAIMR), in support of a ... WAIMR scientists have shared 10 research grants from the ... Research Council (ARC) announced last week placing the Institute,s ...
Cached Medicine News:Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 2Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 3Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 4Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 5Health News:Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 3Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 2Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 3Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 4Health News:National grants further WA Medical Research 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: